HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Research Status of New Targets MRD Detection in Acute Myeloid Leukemia Recurrence--Review].

Abstract
Although most acute myeloid leukemia (AML) patients can achieve complete remission (CR) induced by standardized chemotherapy, but the relapse rate after remission remains high. The key reason is its high heterogeneity in cytogenetics and molecular biology. There are evidences show that minimal residual disease (MRD) is closely associated with disease recurrence, so that, finding specific genetic and molecular biological changes as new targets for MRD detection has become a research hotspot in recent years. In this review the intrinsic relationship between relapse of AML and MRD detection of specific molecular events, the application of these new targets in MRD detection and their targeted therapies according to the latest guidelines, so as to achieve the optimal treatment in CR phase.
AuthorsRen-Le Zhang, Lan-Xia Zhou, Hong-Juan Tian, Li Zhao
JournalZhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 29 Issue 1 Pg. 293-296 (Feb 2021) ISSN: 1009-2137 [Print] China
PMID33554837 (Publication Type: Journal Article, Review)
Topics
  • Flow Cytometry
  • Humans
  • Leukemia, Myeloid, Acute
  • Neoplasm, Residual
  • Prognosis
  • Recurrence
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: